AADC基因治疗中晚期帕金森病三年安全性结果
PD-1101是一项1b期开放标签剂量递增试验,评估AAV2基因疗法VY-AADC01经双侧MRI引导壳核输注治疗伴运动波动的中晚期帕金森病。3个队列各5例,36个月随访未报告归因于载体的严重不良事件,两个高剂量队列左旋多巴需求减少21%-30%,运动功能与生活质量稳定或改善。
要点
- 36个月内未报告归因于VY-AADC01的严重不良事件
- 队列2和3在36个月时帕金森病药物需求减少21%-30%
- 运动功能、总体改善印象与生活质量在各队列稳定或改善
核心结论
- 壳核输注VY-AADC01耐受性良好,3年内运动功能与生活质量稳定或改善,队列2和3的帕金森病药物需求减少。
研究设计与样本
- PD-1101为1b期开放标签剂量递增试验,VY-AADC01为编码人芳香族L-氨基酸脱羧酶(AADC)的AAV2基因疗法。
- 经双侧术中MRI引导壳核输注,分3个队列,每队列5例:队列1 ≤7.5×10^11 vg,队列2 ≤1.5×10^12 vg,队列3 ≤4.7×10^12 vg。
主要发现
- 未报告归因于VY-AADC01的严重不良事件(SAE)。
- 4例非载体相关SAE(1例心房颤动与肺栓塞,另1例2次小肠梗阻)均缓解。
- 36个月时两个最高剂量队列的帕金森病药物需求减少21%-30%。
- PD日记、UPDRS III关期与开期评分、CGI-I、PGI-I及PDQ-39在12、24、36个月较基线稳定或改善。
临床怎么用
- 对伴运动波动的中晚期帕金森病患者,壳核输注VY-AADC01可能作为降低药物需求并稳定运动功能的实验性策略。
局限性
- 为开放标签、无对照、每队列5例的1b期试验,证据等级为Class IV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To report final, 36-month safety and clinical outcomes from the PD-1101 trial of NBIb-1817 (VY-AADC01) in participants with moderately advanced Parkinson disease (PD) and motor fluctuations. METHODS: PD-1101 was a phase 1b, open-label, dose escalation trial of VY-AADC01, an experimental AAV2 gene therapy encoding the human aromatic l-amino acid decarboxylase (AADC) enzyme. VY-AADC01 was delivered via bilateral, intraoperative MRI-guided putaminal infusions to 3 cohorts (n = 5 participants per cohort): cohort 1, ≤7.5 × 1011 vector genomes (vg); cohort 2, ≤1.5 × 1012 vg; cohort 3, ≤4.7 × 1012 vg. RESULTS: No serious adverse events (SAEs) attributed to VY-AADC01 were reported. All 4 non-vector-related SAEs (atrial fibrillation and pulmonary embolism in 1 participant and 2 events of small bowel obstruction in another participant) resolved. Requirements for PD medications were reduced by 21%-30% in the 2 highest dose cohorts at 36 months. Standard measures of motor function (PD diary, Unified Parkinson's Disease Rating Scale III "off"-medication and "on"-medication scores), global impressions of improvement (Clinical Global Impression of Improvement, Patient Global Impression of Improvement), and quality of life (39-item Parkinson's Disease Questionnaire) were stable or improved compared with baseline at 12, 24, and 36 months following VY-AADC01 administration across cohorts. DISCUSSIONS: VY-AADC01 and the surgical administration procedure were well-tolerated and resulted in stable or improved motor function and quality of life across cohorts, as well as reduced PD medication requirements in cohorts 2 and 3 over 3 years. TRIAL REGISTRATION INFORMATION: NCT01973543. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that, in patients with moderately advanced PD and motor fluctuations, putaminal infusion of VY-AADC01 is well tolerated and may improve motor function.
引用
- Christine CW, Richardson RM, Van Laar AD, et al. Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. Neurology. 2021. PMID: 34649873. doi:10.1212/WNL.0000000000012952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。